fentanyl citrate injection usp solution
hikma canada limited - fentanyl (fentanyl citrate) - solution - 50mcg - fentanyl (fentanyl citrate) 50mcg - opiate agonists
fentanyl citrate lozenge
cima labs inc. - fentanyl citrate (unii: mun5lyg46h) (fentanyl - unii:uf599785jz) - fentanyl 200 ug
abstral fentanyl- fentanyl citrate tablet, orally disintegrating
sentynl therapeutics, inc. - fentanyl citrate (unii: mun5lyg46h) (fentanyl - unii:uf599785jz) - fentanyl 100 ug - abstral® is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving, and who are tolerant to, around-the-clock opioid therapy for their underlying persistent cancer pain. patients considered opioid tolerant are those who are taking around-the-clock medicine consisting of at least 60 mg of oral morphine per day, or at least 25 mcg per hour of transdermal fentanyl, or at least 30 mg of oral oxycodone per day, or at least 8 mg of oral hydromorphone per day, or at least 25 mg oral oxymorphone per day, or at least 60 mg oral hydrocodone per day or an equianalgesic dose of another opioid medication daily for a week or longer. patients must remain on around-the- clock opioids when taking abstral® . limitations of use : - not for use in opioid non-tolerant patients. - not for use in the management of acute or postoperative pain, including headache/migraine, dental pain, or in the emergency department [see contraindications (4)]. - as a part of the tirf
fentanyl citrate lozenge
par pharmaceutical inc. - fentanyl citrate (unii: mun5lyg46h) (fentanyl - unii:uf599785jz) - fentanyl 200 ug
abstral- fentanyl citrate tablet
galena biopharma, inc. - fentanyl citrate (unii: mun5lyg46h) (fentanyl - unii:uf599785jz) - fentanyl 100 ug - abstral (fentanyl) sublingual tablets are indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. patients considered opioid tolerant are those who are taking around-theclock medicine consisting of at least 60 mg of oral morphine daily, or at least 25 mcg of transdermal fentanyl/hour, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or at least 25 mg oral oxymorphone daily, or an equianalgesic dose of another opioid medication daily for a week or longer. patients must remain on around-the-clock opioids when taking abstral . abstral is contraindicated for patients who are not already tolerant to opioids because life-threatening respiratory depression and death could result at any dose in patients not on a chronic regimen of opioids. for this reason, abstral is contraindicated in the management of acute or postoperative pain,
fentanyl citrate lozenge
lake erie medical dba quality care products llc - fentanyl citrate (unii: mun5lyg46h) (fentanyl - unii:uf599785jz) - fentanyl 800 ug
lazanda- fentanyl citrate spray
depomed, inc. - fentanyl citrate (unii: mun5lyg46h) (fentanyl - unii:uf599785jz) - fentanyl 100 ug - lazanda is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. patients considered opioid tolerant are those who are taking, for one week or longer, around-the-clock medicine consisting of at least: 60 mg of oral morphine per day, 25 mcg of transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, or at least 25 mg oral oxymorphone per day, or at least 60mg oral hydrocodone per day, or an equianalgesic dose of another opioid for a week or longer. patients must remain on around-the-clock opioids when taking lazanda. limitations of use: - not for use in opioid non-tolerant patients. - not for use in the management of acute or postoperative pain, including headache/migraine, dental pain, or in the emergency department [see contraindications (4)]. - as a part of the tirf rems access program, lazanda may be disp
lazanda- fentanyl citrate spray
archimedes pharma us inc. - fentanyl citrate (unii: mun5lyg46h) (fentanyl - unii:uf599785jz) - fentanyl 100 ug - lazanda (fentanyl) nasal spray is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. patients considered opioid tolerant are those who are taking at least: 60 mg of oral morphine/day, 25 mcg of transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for a week or longer. patients must remain on around-the-clock opioids when taking lazanda. lazanda is contraindicated for patients who are not already tolerant to opioids because life-threatening respiratory depression and death could occur in patients not taking chronic opioids. for this reason, lazanda is contraindicated in the management of acute or postoperative pain, including headache/migraine, or dental pain. [4] lazanda is intended to be prescribed only by healthcare professionals who are knowledgeable of and
fentanyl citrate injection solution
cantrell drug company - fentanyl citrate (unii: mun5lyg46h) (fentanyl - unii:uf599785jz) - fentanyl 10 ug in 1 ml
fentanyl citrate, bupivacaine hcl injection, solution
cantrell drug company - fentanyl citrate (unii: mun5lyg46h) (fentanyl - unii:uf599785jz), bupivacaine hydrochloride (unii: 7tqo7w3vt8) (bupivacaine - unii:y8335394ro) - fentanyl 3 ug in 1 ml